Immune profiles and <scp>HIV</scp> reservoir in people switching to long‐acting cabotegravir/rilpivirine: Findings from a real‐life prospective study
During the first year of treatment, LACR does not significantly impact the HIV reservoir. However, it may reduce immune activation, particularly in persons switching from a dual therapy regimen.
Authors
- Vincenzo Scaglione (ORCID: https://orcid.org/0000-0002-2911-2255)
- Maria Raffaella Petrara (ORCID: https://orcid.org/0000-0003-3609-6107)
- Maria Mazzitelli (ORCID: https://orcid.org/0000-0003-0263-0703)
- Samuele Gardin
- Anna Maria Cattelan (ORCID: https://orcid.org/0000-0003-2869-2945)
- B Vincenzo
- Lolita Sasset
- Beatrice Bragato
- Claudia Cozzolino (ORCID: https://orcid.org/0000-0001-7628-9515)
- Elena Ruffoni (ORCID: https://orcid.org/0000-0003-1574-5702)
- Anita De Rossi (ORCID: https://orcid.org/0000-0001-6435-7509)
- Angela Panese
- Davide Leoni
Institutions
- University of Padua (IT)
- Istituto Oncologico Veneto (IT)
Publication Details
- Journal
- HIV Medicine
- Published
- 2025-05-01
- DOI
- https://doi.org/10.1111/hiv.70030
- Citations
- 3
- Primary Topic
- HIV Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 3.11